Page last updated: 2024-11-13

neolamellarin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

neolamellarin A: from the sponge Dendrilla nigra; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24179369
CHEMBL ID251656
MeSH IDM0539391

Synonyms (3)

Synonym
neolamellarin a
CHEMBL251656
1-[3,4-bis(4-hydroxyphenyl)pyrrol-1-yl]-2-(4-hydroxyphenyl)ethanone

Research Excerpts

Overview

Neolamellarin A is a novel lamellarin-like alkaloid. It was extracted from marine animal sponges.

ExcerptReferenceRelevance
"Neolamellarin A is a novel lamellarin-like alkaloid which was extracted from marine animal sponges."( Protective Effects of Marine Alkaloid Neolamellarin A Derivatives against Glutamate Induced PC12 Cell Apoptosis.
Guan, X; Jiang, T; Liu, L; Yin, R; Zhang, K; Zhang, X, 2022
)
1.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1634239Inhibition of HIF-1 in human HeLa cells transfected with CMV driven renilla luciferase reporter gene incubated for 1 hr under normoxic condition and 12 hrs under hypoxia condition by HRE-based dual luciferase reporter gene assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Structure-activity relationships study of neolamellarin A and its analogues as hypoxia inducible factor-1 (HIF-1) inhibitors.
AID311742Antiproliferative activity against human T47D cells under hypoxic conditions upto 10 uM after 16 to 48 hrs by neutral red assay2007Journal of natural products, Nov, Volume: 70, Issue:11
Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.
AID311751Antiproliferative activity against human T47D cells under normoxic conditions after 48 hrs2007Journal of natural products, Nov, Volume: 70, Issue:11
Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.
AID1634240Cytotoxicity against human HeLa cells assessed as growth inhibition incubated for 60 hrs under normoxic condition by MTT assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Structure-activity relationships study of neolamellarin A and its analogues as hypoxia inducible factor-1 (HIF-1) inhibitors.
AID311741Inhibition of HIF1 activation in T47D cells at 10 uM by reporter gene assay2007Journal of natural products, Nov, Volume: 70, Issue:11
Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.
AID311745Inhibition of 1,10-phenanthroline-induced HIF1 activation in T47D cells at 10 uM by reporter gene assay2007Journal of natural products, Nov, Volume: 70, Issue:11
Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.78 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]